Real4Reg – Unlocking Real-World Data with AI
Real4Reg is a consortium of ten European institutions which aims to promote the use of real-world data (national healthcare registers and claims data) to support the regulatory decisions about medicines. Real4Reg will take advantage of ground-breaking technologies such as artificial intelligence and machine learning.
The structure and approach of our project aim to facilitate the implementation of the effective use of real-world data in regulatory decision-making and health technology assessment.
Data & Methods
Real4Reg will use data sources from four European countries (Denmark, Finland, Germany, and Portugal) and will develop solutions to address the data analytical needs of regulatory agencies.
From a methodological point of view, the project is aligned with the decision-making process in regulatory agencies, which can be broadly broken down into the pre-authorisation, evaluation, and post-authorisation phases of the product lifecycle.
Use Cases
Description of Study population: breast cancer, ALS
Real4Reg will assess the value of real-world data from national healthcare registers and claims data in generating high-quality, accessible, population-based information on breast cancer and amyotrophic lateral sclerosis (considering the diagnosis, treatment, and outcomes).
Historical controls and synthetic data: breast cancer, ALS
Real4Reg will demonstrate how the real-world data can contribute to questions that are not typically answered by clinical trials, due to ethical or practical issues. These questions need to be answered for regulatory evaluation and health technology assessment, in the improvement of external validity and statistical power and precision.
Safety: Fluoroquinolones
The overall objective of this use case is to prepare a good practice example for safety analyses of real-world data for the post-authorisation stage and to improve methods for risk estimation in observational data. Real4Reg will also evaluate the impact of regulatory warnings on the use of broad-spectrum antibiotics.
Effectiveness and drug repurposing: SGLT2 Inhibitors
Real4Reg will prepare a good practice example for drug effectiveness and drug repurposing analyses of real-world data for the drug post-authorisation stage. The case of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors will be analysed. These antidiabetic medicines have shown beneficial effects on cardiovascular outcomes in recent years.
-
Latest News
Real4Reg Partners’ Participation in Key Events: a Brief Recap of 2024
Read more: Real4Reg Partners’ Participation in Key Events: a Brief Recap of 2024As 2025 begins, it’s a good moment to look back at some of the key events that marked the Real4Reg journey in 2024. From important discussions to collaborative initiatives, the past year was full of activities and achievements.
-
Latest News
Real4Reg Shares Insights on RWD External Control Arms at GAA Meeting
Read more: Real4Reg Shares Insights on RWD External Control Arms at GAA MeetingReal4Reg members participated in the 31st Annual Meeting of the German Drug Utilisation Research Group (GAA), held from 21-22 November 2024 at the Federal Institute for Drugs and Medical Devices, BfArM, in Bonn.
Who we are
Our consortium assembles ten partners from six different European countries with experience in the field of RWD analyses, including experts from regulatory agencies and health technology assessment bodies, academia, and patient organisations.
A project for the Patients
Real4Reg integrates two patient organisations to incorporate the patients’ perspectives and expectations along its work.